For the treatment of the following conditions:
- Reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation.
- Deep Vein Thrombosis (DVT)
- Reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE.
- Prophylaxis of deep vein thrombosis which may lead to PE in patients undergoing knee or hip replacement surgery.